Reduced plasma epidermal growth factor levels reflect poor glycaemic status in type 2 diabetes
Open Access
- 15 January 2026
- journal article
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (2)
Abstract
Background: Epidermal growth factor (EGF) plays a crucial role in cellular growth, differentiation, and pancreatic β-cell maintenance. Despite reports on EGF deficiency in diabetic animal models, its relevance in type 2 diabetes (T2D), particularly in relation to obesity, remains underexplored. The present study aimed to evaluate plasma EGF levels in individuals with and without T2D, assess its associations with glycaemic status and clinical parameters, and evaluate the influence of obesity on these relationships. Methods: A total of 838 eligible participants were selected from the Kuwait Diabetes Epidemiology Program. Of those, 428 were included in a 1:1 case–control analysis (214 T2D and 214 non-diabetics). EGF was measured in plasma using ELISA. Associations between EGF with glycaemic and clinical variables were evaluated using Pearson’s correlation, multiple linear regression, and logistic regression analyses. Results: Plasma EGF levels were significantly lower in individuals with T2D compared to non-diabetics (P < 0.001). Among non-diabetics, obese participants had a significantly lower EGF level than their non-obese counterparts (P = 0.03), while no such difference was observed in T2D. EGF negatively correlated with fasting blood glucose in both non-diabetics (P = 0.004) and T2D individuals (P < 0.001). In T2D, EGF negatively correlated with haemoglobin A1C (HbA1C) (P = 0.001), triglyceride (TG) (P = 0.021), and waist-to-hip ratio (WHR) (P = 0.014). Logistic regression confirmed that lower EGF levels were independently associated with T2D but not with general obesity (OR = 0.996, P = 0.001). Conclusion: Reduced EGF levels are associated with poor glycaemic control in T2D. These findings highlight EGF’s potential as a biomarker for glycaemic dysregulation and support further investigation into its role in diabetes pathophysiology and complications.Keywords
This publication has 34 references indexed in Scilit:
- Elevated C-Reactive ProteinArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation.2000
- Elevated C-Reactive Protein Levels in Overweight and Obese AdultsJAMA, 1999
- Apolipoproteins in human fetal colon: immunolocalization, biogenesis, and hormonal regulation.1998
- Inhibition of apolipoprotein B secretion by IL-6 is mediated by EGF or an EGF-like molecule in CaCo-2 cellsJournal of Lipid Research, 1997
- Apolipoprotein Synthesis in Human Fetal Intestine: Regulation by Epidermal Growth FactorBiochemical and Biophysical Research Communications, 1994
- Growth Factors and Diabetic ComplicationsDiabetic Medicine, 1990
- Distribution, release, and secretory activity of epidermal growth factor in the pancreasInternational journal of pancreatology, 1990
- Epidermal growth factor deficiency associated with diabetes mellitus.Proceedings of the National Academy of Sciences, 1989
- Effect of streptozotocin-induced diabetes on epidermal growth factor receptors in rat liver plasma membraneBiochimica et Biophysica Acta (BBA) - General Subjects, 1987